Gene synthesis companies establish measures to counter bioterrorism
By European Biotechnology Science and Industry News,
European Biotechnology Science and Industry News
| 11. 20. 2009
The five largest suppliers of synthetic DNA will establish common measures to prevent misuse of synthetically produced DNA by bioterorrists or criminals. Yesterday, Blue Heron Biotechnology, DNA2.0, GENEART, GenScript and Integrated DNA Technologies, which together represent an 80% share of the synthetic DNA market, announced the establishment of a common screening protocol that will be applied to every single synthetic gene order. "We are proud to announce the formation of the International Gene Synthesis Consortium", said John Mulligan, CSO of Blue Heron Biotechnology.
The IGSC's "Harmonized Screening Protocol" is comprised of the screening of gene sequences against a regulated pathogen database developed by the consortium and one or more of the internationally coordinated sequence reference databanks, such as NCBI/GenBank, EBI/EMBL, or DDBJ. Amino acid sequences of possible translation products for each ordered synthetic gene will also be screened. Purchasers of synthetic genes will also be screened in accordance with national guidelines. Furthermore, the IGSC companies have agreed to keep all screening, customer, and order records for at least eight years. IGSC companies have also reserved the right to refuse to...
Related Articles
By Carly Mallenbaum, Axios [cites Emily Galpern] | 03.29.2026
More Americans are turning to surrogacy to build their families, as the practice becomes more common and more publicly discussed.
Why it matters: As surrogacy becomes more visible and accessible, ethical, legal and cultural tensions become harder to ignore...
By David Jensen, The California Stem Cell Report | 03.26.2026
SACRAMENTO, Ca. -- California’s $12 billion stem cell and gene therapy program scored a historic first today, announcing that it had for the first time helped to finance a revolutionary treatment that will now be available to the general public...
Cathy Tie seems to be good at starting businesses but not so dedicated to maintaining them. CGS, like many others, first heard of her thanks to Caiwei Chen and Antonio Regalado in MIT Technology Review, May 2025, as the partner (perhaps bride) of the notorious Chinese scientist He Jiankui, described in the headline as “China’s Frankenstein.” He prefers “Chinese Darwin.” She ran his Twitter account for a while, contributing such gems as:
Get in luddite, we’re going gene editing...
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...